Evaluation of the Anti-diabetic Property of Morinda lucida Leaves in Streptozotocin-diabetic Rats
Article first published online: 18 FEB 2010
1999 Royal Pharmaceutical Society of Great Britain
Journal of Pharmacy and Pharmacology
Volume 51, Issue 11, pages 1321–1324, November 1999
How to Cite
OLAJIDE, O. A., AWE, S. O., MAKINDE, J. M. and MOREBISE, O. (1999), Evaluation of the Anti-diabetic Property of Morinda lucida Leaves in Streptozotocin-diabetic Rats. Journal of Pharmacy and Pharmacology, 51: 1321–1324. doi: 10.1211/0022357991776903
- Issue published online: 18 FEB 2010
- Article first published online: 18 FEB 2010
- Received April 15, 1999 Accepted June 21, 1999
The hypoglycaemic and anti-hyperglycaemic activities of a methanol extract of Morinda lucida Benth. (Rubiaceae) leaves were studied in normal and streptozotocin-diabetic rats.
In normal rats, the extract demonstrated a significant (P < 0.05) and dose-dependent hypoglycaemic activity within 4h after oral administration. The plasma glucose level of 400 mg kg−1 of the extract at 4h was 42.5 ± 0.4 mg/100 mL (control 67.4 ± 1.2 mg/100 mL). After 12h, the plasma glucose level of rats administered 50, 100, 200 or 400 mg kg−1 extract fell to 51.9 ± 1.2, 47.3 ± 0.8, 43.1 ± 0.4 and 40.0 ± 0.5 mg/100 mL, respectively. In hyperglycaemic rats, the extract produced a significant (P < 0.05) anti-diabetic effect from day 3 after oral administration, with 400 mg kg−1 extract-treated animals having a plasma glucose level of 248.7 ± 5.3 mg/100 mL compared with glibenclamide (10 mg kg−1)-treated animals with a plasma glucose level of 251.5 ± 5.8 mg/100 mL.
These results suggest that the leaves of Morinda lucida have a strong glucose lowering property when administered to streptozotocin-treated rats.